Eryptosis: a driver of anemia in chronic kidney disease.

Abstract

PURPOSE OF REVIEW:

Anemia, characterized by a reduction in red blood cell (RBC) count or hemoglobin concentration, commonly accompanies chronic kidney disease (CKD), significantly impacting patients' quality of life. This review delves into the multifaceted nature of anemia in CKD, with a focus on novel mechanisms, particularly the dysregulation of eryptosis or programmed cell death of RBCs, leading to shortened RBC lifespan.

RECENT FINDINGS:

Recent studies in CKD patients and mouse models revealed that eryptosis, driven by factors such as uremic toxins, inflammation, and imbalances in calcium homeostasis, plays a pivotal role in the development of renal anemia. Dysregulated eryptosis results in premature RBC destruction, exacerbating the hypoproliferative character of anemia in CKD.

SUMMARY:

Recognizing the intricate relationship between eryptosis and anemia in CKD opens promising prospects for improving patient outcomes and enhancing our understanding of this complex condition. Future research and therapeutic development in this area hold the potential to improve anemia treatment of CKD patients.

• Authors: Rosi Bissinger, Syed M Qadri, Ferruh Artunc
• Journal: Current opinion in nephrology and hypertension (Curr Opin Nephrol Hypertens) Vol. 33 Issue 2 Pg. 220-225 (Mar 01 2024) ISSN: 1473-6543 [Electronic] England
• PMID: 37987655 (Publication Type: Review, Journal Article)
• Copyright: Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Topics

• Animals
• Mice
• Humans
• Eryptosis
• Quality of Life
• Anemia (etiology, metabolism)
• Erythrocytes (metabolism)
• Renal Insufficiency, Chronic (complications, metabolism)